Abstract 5311: Proteomic characterization of zoledronic acid-resistant prostate cancer cells identified key proteins in cytoskeleton organization and cancer stem cell markers associated with a very aggressive phenotype

The aminobiphosphonate Zoledronic acid (ZOL) inhibit osteoclast-mediated bone resorption and it is used to prevent skeletal complications from bone metastases. Accumulating evidences in both preclinical and clinical studies indicated that ZOL might also have anticancer activity. We have recently selected for the first time the ZOL-resistant DU145R80 prostate cancer (PCa) cell line that demonstrated an antiapoptotic and proangiogenic phenotype with increased invasive capability and epithelial to mesenchymal transition (EMT), compared to parental DU145 cells. Interestingly, we also demonstrated that both the acquired resistance to ZOL and the aggressive phenotype are mediated by p38-MAPK (Milone et al. Cell Death Dis. 2013, 4:e641). To further investigate the mechanism of ZOL-resistance and of the parallel acquisition of an aggressive phenotype in this novel syngeneic model of PCa, we took advantage of a two-dimensional difference gel electrophoresis (2D-DIGE)/mass spectrometry (MS) proteomic approach, to investigate differential expressed proteins between DU145R80 and DU145 cell lines. We found 21 statistically differentially expressed protein spots between the two cell lines (average volume ratio threshold of ±1.4-fold and 95% level of significance, p
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Molecular and Cellular Biology Source Type: research